DIAGNOS Inc. (DGNOF)
OTCMKTS · Delayed Price · Currency is USD
0.2425
+0.0138 (6.05%)
Oct 24, 2025, 3:25 PM EDT
DIAGNOS Revenue
DIAGNOS had revenue of 19.40K CAD in the quarter ending June 30, 2025, a decrease of -47.12%. This brings the company's revenue in the last twelve months to 86.51K, down -47.10% year-over-year. In the fiscal year ending March 31, 2025, DIAGNOS had annual revenue of 103.80K, down -39.00%.
Revenue (ttm)
86.51K CAD
Revenue Growth
-47.10%
P/S Ratio
399.73
Revenue / Employee
3.93K CAD
Employees
22
Market Cap
25.35M USD
Revenue Chart
* This company reports financials in CAD.
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Mar 31, 2025 | 103.80K | -66.36K | -39.00% |
| Mar 31, 2024 | 170.16K | -315.59K | -64.97% |
| Mar 31, 2023 | 485.75K | 46.92K | 10.69% |
| Mar 31, 2022 | 438.83K | 171.76K | 64.31% |
| Mar 31, 2021 | 267.07K | -64.44K | -19.44% |
| Mar 31, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Mar 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Mar 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Mar 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Mar 31, 2016 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| American Oncology Network | 1.76B |
| Veradigm | 588.02M |
| Jushi Holdings | 256.36M |
| Glass House Brands | 221.55M |
| Elite Pharmaceuticals | 105.45M |
| Silence Therapeutics | 27.17M |
| Nuo Therapeutics | 1.95M |
| Northwest Biotherapeutics | 1.09M |
DIAGNOS News
- 11 days ago - DIAGNOS to Present at the Centurion One Capital 3rd Annual Bahamas Summit - Newsfile Corp
- 4 weeks ago - DIAGNOS Announces Voting Results of Meeting of Shareholders - GlobeNewsWire
- 7 weeks ago - DIAGNOS Announces Closing of Private Placement - GlobeNewsWire
- 2 months ago - DIAGNOS to Extend Stock Warrants Exercise Period - GlobeNewsWire
- 2 months ago - DIAGNOS Announces Extension of Stock Warrants Exercise Period - GlobeNewsWire
- 4 months ago - DIAGNOS Welcomes Founder of National Vision Associates, Ed Weiner, to its Advisory Board for the United States - GlobeNewsWire
- 5 months ago - DIAGNOS Welcomes Former White House Economic Adviser Dr. Tomas J. Philipson to its Advisory Board for the US Market - GlobeNewsWire
- 5 months ago - DIAGNOS Announces the Engagement of Allele Capital Partners - GlobeNewsWire